| Autor: |
Aljinović J; Division of Physical Medicine and Rehabilitation with Rheumatology, University Hospital of Split, 21000 Split, Croatia.; University of Split School of Medicine, 21000 Split, Croatia.; University of Split, Department of Health Studies, 21000 Split, Croatia., Šošo D; Division of Physical Medicine and Rehabilitation with Rheumatology, University Hospital of Split, 21000 Split, Croatia.; University of Split, Department of Health Studies, 21000 Split, Croatia., Petrić M; Department of Internal Medicine, Division of Rheumatology, Allergology and Clinical Immunology, University Hospital of Split, 21000 Split, Croatia., Perković D; University of Split School of Medicine, 21000 Split, Croatia.; Department of Internal Medicine, Division of Rheumatology, Allergology and Clinical Immunology, University Hospital of Split, 21000 Split, Croatia., Marasović Krstulović D; University of Split School of Medicine, 21000 Split, Croatia.; Department of Internal Medicine, Division of Rheumatology, Allergology and Clinical Immunology, University Hospital of Split, 21000 Split, Croatia., Kero D; Study Program of Dental Medicine, University of Split School of Medicine, 21000 Split, Croatia., Marinović I; Division of Physical Medicine and Rehabilitation with Rheumatology, University Hospital of Split, 21000 Split, Croatia.; University of Split, Department of Health Studies, 21000 Split, Croatia. |
| Abstrakt: |
Objective: The genetic background of HLA-B*27 in spondyloarthritis is known, and the search for another gene with similar role is ongoing. We wanted to investigate clinical presentations of HLA-B*44 patients in rheumatology practice. Methods: A cross-sectional retrospective study of 303 HLA-B*44 adult patients from the outpatient rheumatology clinic from 5/2018-5/2024. Clinical phenotype, confirmed or excluded rheumatic diagnosis, therapy used, and data on HLA A, B, and DR alleles inherited with B*44 were analyzed. Results: A female predominance of 2.79:1 was noted. A total of 150 [49.5%] patients were referred due to peripheral joint pain, 77 [25.4%] due to combined spine and peripheral joint pain or spine alone (57 [18.8%]). A total of 19 [6.3%] patients had no symptoms of the musculoskeletal system. Statistically significant peripheral joint affection was proved in females but not in males ( p = 0.04). A total of 121 [40%] patients from B*44 group had established rheumatic disease, with the rest being excluded or under observation. The most common working diagnoses were polyarthritis (32 [10.5%]) and mono-oligoarthritis (14 [4.6%]). A second allele in addition to HLA B*44 showed a similar frequency to the general population. Patients with HLA B*44/44 and B*27/44 genotypes were at the most risk for having definitive rheumatic disease (>60%). Conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) were used in 38.6% of patients, non-steroidal anti-inflammatory drugs were used in 31.6% of patients, biologic DMARDs were used in 8.9% of patients, and corticosteroids were used in 7.3% of patients. Conclusions: The most common presentation in HLA-B*44 patients is peripheral joint affection. Most patients with HLA-B*27/44 and B*44/44 genotypes had definitive rheumatic disease. B*44 homozygosity or B*27/44 might be risk factors for arthritis development. |
